Skip to main content

Table 1 Clinical characteristics of patients with gastric cancer receiving adjuvant TS-1 and 5-fluorouracil chemotherapy

From: Total gastrectomy increases the incidence of grade III and IV toxicities in patients with gastric cancer receiving adjuvant TS-1 treatment

  TS-1 adjuvant group, n (%) 5-fluorouracil adjuvant group, n (%) p value
Total 40 (100) 193 (100)  
Male gender 24 (60) 123 (63.7) 0.39
Median age (range) 61.0 (27 to 88) 61.1 (27 to 90) 0.63
ECOG performance status scale    
 0 32 (80) 133 (68.9) 0.24
 1 7 (17.5) 47 (24.4)  
 2 1 (2.5) 13 (6.7)  
Histological type    
 Intestinal 15 (37.5) 61 (31.6) 0.29
 Diffuse 25 (62.5) 132 (68.4)  
Gastrectomy method    
 Subtotal 25 (62.5) 124 (64.2) 0.48
 Total 15 (37.5) 69 (35.8)  
TNM stage (AJCC, 6 th )    
 Ib 5 (12.5) 48 (24.9) 0.12
 II 17 (42.5) 46 (23.8)  
 IIIa 8 (20) 51 (26.4)  
 IIIb 2 (5) 13 (6.7)  
 IV 8 (20) 35 (18.1)  
Tumor stage (AJCC, 6 th )    0.14
 T1 6 (15) 45 (23.3)  
 T2 22 (55) 68 (35.2)  
 T3 9 (22.5) 59 (30.6)  
 T4 3 (7.5) 21 (10.9)  
Nodal stage (AJCC, 6 th )    
 N0 2 (5) 28 (14.5) 0.28
 N1 23 (57.5) 97 (50.3)  
 N2 9 (22.5) 50 (25.9)  
 N3 6 (15) 18 (9.3)  
  1. AJCC, American Joint Committee on Cancer; ECOG, Eastern Cooperative Oncology Group; TNM, Tumor-node-metastasis.